Literature DB >> 25890492

How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy?

F Martinelli1, G Bogani2, A Ditto1, M Carcangiu3, A Papadia1, F Lecce1, V Chiappa1, D Lorusso1, F Raspagliesi1.   

Abstract

OBJECTIVE: Parametrial involvement (PMI) is one of the most important factors influencing prognosis in locally advanced stage cervical cancer (LACC) patients. We aimed to evaluate PMI rate among LACC patients undergoing neoadjuvant chemotherapy (NACT), thus evaluating the utility of parametrectomy in tailor adjuvant treatments.
METHODS: Retrospective evaluation of consecutive 275 patients affected by LACC (IB2-IIB), undergoing NACT followed by type C/class III radical hysterectomy. Basic descriptive statistics, univariate and multivariate analyses were applied in order to identify factors predicting PMI. Survival outcomes were assessed using Kaplan-Meier and Cox models.
RESULTS: PMI was detected in 37 (13%) patients: it was associated with vaginal involvement, lymph node positivity and both in 10 (4%), 5 (2%) and 12 (4%) patients, respectively; while PMI alone was observed in only 10 (4%) patients. Among this latter group, adjuvant treatment was delivered in 3 (1%) patients on the basis of pure PMI; while the remaining patients had other characteristics driving adjuvant treatment. Considering factors predicting PMI we observed that only suboptimal pathological responses (OR: 1.11; 95% CI: 1.01, 1.22) and vaginal involvement (OR: 1.29 (95%) CI: 1.17, 1.44) were independently associated with PMI. PMI did not correlate with survival (HR: 2.0; 95% CI: 0.82, 4.89); while clinical response to NACT (HR: 3.35; 95% CI: 1.59, 7.04), vaginal involvement (HR: 2.38; 95% CI: 1.12, 5.02) and lymph nodes positivity (HR: 3.47; 95% CI: 1.62, 7.41), independently correlated with worse survival outcomes.
CONCLUSIONS: Our data suggest that PMI had a limited role on the choice to administer adjuvant treatment, thus supporting the potential embrace of less radical surgery in LACC patients undergoing NACT. Further prospective studies are warranted.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant treatment; Neoadjuvant chemotherapy; Parametrectomy; Parametrial involvement; Radical hysterectomy

Mesh:

Year:  2015        PMID: 25890492     DOI: 10.1016/j.ejso.2015.03.228

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  The Effect of Neoadjuvant Chemotherapy on Lymph Node Metastasis of FIGO Stage IB1-IIB Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Bingxin Chen; Liming Wang; Ci Ren; Hui Shen; Wencheng Ding; Da Zhu; Lu Mao; Hui Wang
Journal:  Front Oncol       Date:  2020-11-05       Impact factor: 6.244

2.  Influence of MDR1 methylation on the curative effect of interventional embolism chemotherapy for cervical cancer.

Authors:  Zhi Huang; Shuai Zhang; Yaping Shen; Weixin Liu; Jipu Long; Shi Zhou
Journal:  Ther Clin Risk Manag       Date:  2016-02-15       Impact factor: 2.423

3.  Meta-analysis showing that early response to neoadjuvant chemotherapy predicts better survival among cervical cancer patients.

Authors:  Zhilan Chen; Yachen Shi; Shixuan Wang; Qiping Lu
Journal:  Oncotarget       Date:  2017-07-21

4.  Expression of VEGF and HIF-1α in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis.

Authors:  Pengfeng Zhu; Yangjun Ou; Yishan Dong; Peizhen Xu; Lei Yuan
Journal:  Onco Targets Ther       Date:  2016-05-23       Impact factor: 4.147

5.  Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy.

Authors:  Zhilan Chen; Kecheng Huang; Zhiyong Lu; Song Deng; Jiaqiang Xiong; Jia Huang; Xiong Li; Fangxu Tang; Zhihao Wang; Haiying Sun; Lin Wang; Shasha Zhou; Xiaoli Wang; Yao Jia; Ting Hu; Juan Gui; Dongyi Wan; Ding Ma; Shuang Li; Shixuan Wang
Journal:  Onco Targets Ther       Date:  2016-05-27       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.